In an attempt to combine the human immunodeficiency virus type 1 (HIV-D-inhibitory capacity of 2′,3 -dideoxy-2,3 -didehydronucleoside analogues [nucleoside reverse transcriptase (RT) inhibitors; NRTI] and non-nucleoside RT inhibitors (NNRTI), we have designed, synthesized and evaluated for their anti-HIV activity several heterodimers of the general formula [d4T]-NH-(CH2)n-NH-[imidazo[1,5–b]pyridazine]. The synthesis of these heterodimers was conducted in three parts. The first part focused on the synthesis of the NRTI. The second part was devoted to the NNRTI and the NNRTI linked to appropriate spacers; [NNRTI]-NH-(CH2)n-NH2. In the third part, the condensation between the NRTI and the [NNRTI]-NH-(CH2)n-NH2 was performed. The in vitro inhibitory activities against HIV-1 of the [d4T]-NH-(CH2)n-NH-[imidazo[1,5–b]pyridazine] heterodimers were found to be comparable to that of d4T (stavudine) in HIV-infected cells. Moreover, the heterodimers were endowed with anti-HlV-2 activity and with anti-nevirapine-resistant HIV-1 activity. None of the heterodimers proved markedly cytotoxic to CEM-SS or MT-4 cells. There was not a clear trend toward antiviral potency on lengthening the methylene spacer in the [d4T]-NH-(CH2)n-NH-[imidazo[1,5–b]pyridazine] heterodimers.
BabaMPauwelsRHerdewijnPDe ClercqEDesmyterJ & VandeputteM (1987a) Both 2′,3′-dideoxythymidine and its 2′,3′-unsaturated derivative (2′,3′-didehydro-2′,3′-didcoxyrhymidine) are potent and selective inhibitors of human immunodeficiency virus replication in vitro. Biochemical and Biophysical Research Communications142:128–134.
2.
BabaMPauwelsRBalzariniJHerdewijnP & De ClercqE (1987b) The inhibition of human immunodeficiency virus (HIV) by 3′-azido-2′,3′-didcoxyguanosine in vitro. Biochemical and Biophysical Research Communications145:1080–1086.
3.
BabaMTanakaHDe ClercqEPauwelsRBalzariniJScholsDNakashimaHPernoCFWalkerRT & MiyasakaT (1989) Highly specific inhibition of human immunodeficiency virus type 1 by a novel 6–substituted acyclouridine derivative. Biochemical and Biophysical Research Communications165:1375–1331.
4.
BabaMDe ClercqETanakaHUbasawaMTakashimaHSekiyaKNittaIUmezuKNakashinaHMoriSShigetaSWalkerRT & MiyasakaT (1991) Potent and selective inhibition of human immunodeficiency virus type 1 (H1V-1) by 5–ethyl-6–phenyithiouracil derivatives through their interaction with the HIV-1 reverse transcriptase. Proceedings of the National Academy of Sciences. USA88:2356–2360.
5.
BalzariniJKangGJDalaiMHerdewijnPDe ClercqEBroderS & JohnsDG (1987) The anti-HTLV, anti-HIV and cytotoxic activity of 2′,3′-didehydro-2′,3′-dideoxyribonucleosides. A comparison with their parental 2′,3′-dideoxyribonucleosides. Molecular Pharmacology32:162–167.
6.
BalzariniJPauwelsRBabaMHerdewijnPDe ClercqEBroderS & JonhsDG (1988a) The in vitro and in vivo antiretrovirus activity and intracellular metabolism of 3′-azido-2′,3′-dideoxythymidine and 2′,3′-dideoxycytidine are highly dependent on the cell species. Biochemical Pharmacology37:897–903.
7.
BalzariniJPauwelsRBabaMHerdewijnP & De ClercqE (1988b) Antiretrovirus activity of 3′-fiuoro and 3′-azido substituted pyrimidine-2′,3′-dideoxynucleoside analogues. Biochemical Pharmacology37:2847–2856.
8.
BalzariniJNaesensL & HerdewijnP (1989) Marked in vivo anti retrovirus activity of 9-(2-phosphi)nylmethnoxycthyl)adenine, a selective anti-human immunodeficiency virus agent. Proceedings of the National Academy of Sciences, USA86:332–336.
9.
BalzariniJPerez-PerezMJSan FelixAScholsDPernoCFVandammeAMCamarasaMJ & De ClercqE (1992) 2′,5′-Bis-O-(tert-butyldimethylsilyl)-3′-spiro 5“-(4”-amino-1“,2”-oxathiole-2“,2”-dioxide) pyrimidine (TSAO) nucleoside analogues. Highly selective inhibitors of human immunodeficiency virus type 1 that arc targeted at the viral reverse transcriptase. Proceedings of the National Academy of Sciences, USA89:4398–4396.
10.
BalzariniJKarlssonAPerez-PerezMJVrangLWalbersJZhangHÖbergBVandammeAMCamarasaMJ & De ClercqE (1993a) HIV-1–specific reverse transcriptase inhibitors show differential activity against HIV-1 mutant strains containing different amino acid substitutions in the reverse transcriptase. Virology192:246–253.
11.
BalzariniJKarlssonAPerez PerezMJCamarasaMJTarpleyWG & De ClercqE (1993b) Treatment of human immunodeficiency virus type 1 (HIV-I)-infected cells with combinations of H1V-1–specific inhibitors results in a different resistance pattern than does treatment with single-drug therapy, Journal of Virology67:5353–5359.
12.
BoyerPLCurrensMJMcMahonJBBoydMR & HuguesSH (1993) Analysis of non-nucleoside drug-resistant variants of human immunodeficiency virus type I reverse transcriptase. Journal of Virology67:2412–2420.
13.
BrowneMJMayerKHChafeeSBDudleyMNPosnerMRSteinbergSMGrahamKKGeletkoSMZinnerSHDenmanSLDunkleLMKaulSMcLarenCSkowronCKontlabNMKennedyTAWeitbergAB & CurtGA (1993) 2′,3′-didchydro-3′-deoxythymidine (d4T) in patterns with Aids or Aids related complex, a phase I trial. Journal of Infectious Diseases167:21–29.
14.
BuckheitRWWhiteELGermany-DeckerJAllenLBRossLJShannon WM JanssenPAJ & ChirigosMA (1994) Cell-based and biochemical analysis of the anti-HIV activity of combination of 3′-azido-3′-deoxythymidinc and analogues of TIBO. Antiviral Chemistry & Chemotherapy5:35–42.
15.
CamarasaMJPérez-PérezMJSan-FelixABalzariniJ & De ClercqE (1992) 3′-spiro nucleosides, a new class of specific human immunodeficiency virus type [inhibitors: synthesis and antiviral activity of [2′,5′-bis-O-(tert-butyldimethylsilyl)-β-d-xylo and riborufranose]-3′-spiro-5“-[(4”-amino-1“,2”-oxathiole-2“,2”-dioxide) pyrimidine and pyrimidine modified nucleosides. Journal of Medicinal Chemistry35:2988–2995.
16.
ChouJ & ChouTC (1985) Dose–effect analysis with microcomputers: quantitation of ED50, LD50, synergism, antagonism, low-dose risk, receptor binding and enzyme kinetics. In Computer Software for Apple II Series and IBM-PC and Instruction Manual, pp. 19–28, Cambridge: Elsevier-Biosoft.
17.
ClassonBPerJ & GareggB (1982) A facile preparation of 2′,3′-unsarurated nucleoside and hexopyranosides from acetylated halohydrins by reductive elimination. Acta Chemica Scandanavica B36:251–253.
18.
CrettonEMXieMYBevanRJGoodgaonNMSchinaziRF & SommadossiJP (1991) Catabolism of 3′-azido-3′-deoxythymidine in hepatocytes and liver microsomes with evidence of formation of 3′-amino-3′-dcoxythymidine, a highly toxic calabolite for human bone marrow cells. Molecular Pharmacology39:258–266.
19.
De ClercqE (1992) HIV inhibitors targeted at the reverse transcriptase. AIDS Research and Human Retroviruses8:119–134.
20.
De ClercqE (1994) HIV resistance to reverse transcriptase inhibitors. Biochemical Pharmatology47:155–169.
21.
De VreeseKDebyserZVandammeAMPauwelsRDesmyterJ & De ClercqE (1992) Resistance of human immunodeficiency virus type 1 reverse transcriptase to TTBO derivatives induced by site-directed mutagenesis. Journal of Virology188:900–904.
22.
DiviraGMüllerBImmendörferUGautelMRittingerKRestleT & GoodyRS (1993) Kinetics of interaction of HIV reverse transcriptase with primer/template. Biochemistry32:7966–7971.
23.
EminiEAStarzewskiSSchneiderCLWaterburyJASchleifWAGochlerRDeussenADuerrSMassariFECalandraGBHoffstedrB & ByrnesVW (1993) Combination therapy with AZT prevents selection of HIV-1 variants that are highly resistant to the nonnucleoside reverse transcriptase inhibitor L-697,661. Antiviral Research20 (Suppl. 1);94.
24.
FischlMARichmanDDGriecoMHGottliebMSVolberdingPALaskinOLLeedomJMMildvanDSchooleyRTJacksonGCDurackDT & KingD (1987) The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. New England Journal of Medicine317:185–191.
25.
GaoQGuZPamiakMALinX & WeinbergMA (1992) In vitro selection of variants of human immunodeficiency virus type 1 resistant to 3′-azido-3′-deoxythymidine. Journal of Virology66:12–19.
26.
GoldmanMENunbergJHO'BrienJAQuinteroJCSchleifWAFreundKFGaulSLSaariWSWaiJSHoffmanJMAndersonPSHaveDJEminiEA & SternAM (1991) Pyridinone derivative: specific human immunodefiency virus type 1 reverse transcriptase inhibitors with antiviral activity. Proceedings of the National Academy of Sciences, USA88:6863–6867.
27.
GrabPMWuJCCohenKASt MerluzziVJ (1993) Nonnuclcoside inhibitors of HIV-1 reverse transcriptase nevirapine as a prototype drug. AIDS Research and Human Retroviruses8:145–152.
28.
HanasakiVWaranabeHKatsuuraKTakayamaHShirakawaSYamaguchiKSakaiSIjichiKFujiwaraMKonnoKYokotaTShigetaS & BabaM (1995) Thiadiazole derivatives: highly potent and specific HIV-1 reverse transcriptase inhibitors. Journal of Medicinal Chemistry38:2038–2040.
29.
HiziATalRShahabanyMCurrensMJHuguesSH & McMahonJB (1993) Specific inhibition of the reverse transcriptase of human immunodeficiency virus type I and the chimeric enzymes of human immunodeficiency virus type I and type II by nonnuclcoside inhibitors. Antimicrobial Agents & Chemotherapy37:1037–1042.
30.
IjichiKFujiwaraMMoriKMorozumiMMachidaHShigetaSKonnoKYokotsT & BabaM (1596) Antiviral activities of nucleotide heterodimers against human immunodeficiency virus type 1 in vitro. Antiviral Research31:115–120.
31.
IkedaKTanakaS & MizunoY (1975) Syntheses of 5-carbomethoxy methyl- and 5-methylamino-methyl-2-thiouridine (the ‘first letters’ of some anticodons) and closely related nucleosides from uridine. Chemical and Pharmaceutical Bulletin23:2958–2964.
32.
JapourAJChatisPAEigenrauchHA & CrumpakerCS (1991) Detection of human immunodeficiency virus type I clinical isolates with reduced sensitivity to zidovudine and dideoxyinosine by RNA-RNA hybridation. Proceedings of the National Academy of Sciences, USA88:3092–3096.
33.
KellamPBoucherCABSt LarderBA (1992) Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to development of high-level resistance to zidovudine. Proceeding; of the National Academy of Sciences, USA89:1934–1938.
34.
KohlstaedtLAWangJFriedmanJMRicePASt SteiztTA (1992) Crystal structure at 3.5A of HIV-1 reverse transcriptase completed with an inhibitor. Science256:1783–1790.
35.
KoupRAMerluzziVJHargraveKDAdamsJGrozingerKEcknerKSt SullivanJL (1991) Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by the dipyridodiazepinone BI-RG-587. Journal of Infectious Diseases163:966–970.
36.
LarderBADarbyG & RichmanDD (1989) HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science243:1731.
37.
LarderBASt KempSD (1989) Multiple mutation in HIV-1 reverse transcriptase confer high level resistance to zidovudine (AZT). Science246:1155.
38.
LarderBA (1992) 3′-azido-3′-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to non-nucleoside reverse transcriptase inhibitors. Antimicrobial Agents & Chemotherapy36:2664–2669.
39.
LefehvreIPerigaudCPomponAAubertinAMGitardetJLKirnAGosselinG & ImbachJL (1995) Mononucleoside phosphorriester derivatives with S-acyl-2–thioethyl bioreversible phosphate-protecting groups: intracellular delivery of 3′-azido-2′,3′-dideoxythvmidinc 5′-monaphosphate. Journal of Medicinal Chemistry38:3941–3950.
40.
LinTSchinaziRF & PrusoffWH (1987) Potent and selective invitro activity of 3′-deoxythymidin-2-ene (3′-deoxy-2′,3′-didchydrothymidine) against human immunodeficiency virus. Biochemical Pharmacology36:2713–2718.
41.
LivermoreDHGBethellRCCammackNHancockAPHannMMGreenDVSLamentRBNobleSAOrrDCPayneJJRamsayVJShinglerAHSmithCStorerRWilliamsonCSt WillsonT (1993) Synthesis and anti HIV-1 activity of a series of imidazo[1,5-b]pyridazines. Journal of Medicinal Chemistry36:3784–3794.
42.
MansuriMMStarrestJEGhazzouliIHitchcockMJMSterzyckiRZBrankovanVLinTAugustEMPrusoffWHSommadossiJ & MartinJC (1989a) 1–(2,3–dideoxy-β-d-glycero-penr-2–enofuranosyl) thymine. A highly potent and selective HIV agent. Journal of Medicinal Chemistry32:461–466.
43.
MansuriMMStarrettJEJrWosJATortolaniDRBrodfuehrerPRHowellHG & MartinJC (1989b) Preparation of 1(2,3-dideoxy-β-d-glycero-pent-2-enofuranosyl) thymine d4T and 2′,3′-dideoxyadenosine (ddA): general methods for the synthesis of 2′,3′-olefinic and 2′,3′dideoxy nucleoside analogues active against HIV. Journal of Organic Chemistry4780–4785.
44.
MarumotoR & HonjoM (1974) One-step halogenation at the 2′ position of uridine and related reaction of cytidine and N4 acerylcytidine. Chemical and Pharmaceutical Bulletin22:128–134.
45.
MauryG & DivitaG (1995) Les progres recents dans la connaissance de la structure de la transcriptase inverse du virus d'immunodéficience humaine suggèrent-ils la conception et la synthese de nouveaux inhibiteurs de l'enzyme et de nouvelles drogues anti-SIDA. Bulletin de la Societe Chimique de France132:1095–1102.
46.
MeriganTCSkowronGBozzetteSARichmanDDRittamchandaniRFischlMASchooleyRTHirchMSooWPertinelliC & SchaumburgH (1989) The ddC study group of the AIDS clinical trials group circulating p24 antigen levels and responses to didcoxycytidine in human immunodeficiency virus (HIV) infections. Annals of Internal Medicine110:189–194.
47.
MellorsJWDutschmanGEImGJTramontanoEWinklerSR & CheuqYC (1992) In vitro selection and molecular characterization of human immunodeficiency virus-1 resistant to non nucleoside inhibitors of reverse transcriptase. Molecular Pharmacology41:446–451.
48.
MerluzziVJHargraveKDLabadiaMGrozingerKSkoogMWuJCShihCKEcknerKHattoxSAdamsJRosenthalASFaanesREcknerRJKoupRA & SullivanJC (1990) Inhibition at HIV-1 replication by a non nucleoside reverse transcriptase inhibitor. Science250:1411–1413.
49.
MirsuyaHWeinholdKJFurmanPASt ClairMHNusinoff LehrrnanSGalloRCBolognesiDBarryDWSt BroderS (1985) 3′-azido,3′-deoxythymidine (SWA 509 U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy associated virus in vitro. Proceedings of the National Academy of Sciences. USA82:7096–7100.
50.
MitsuyaHYarchoanR & BroderS (1990) Molecular targets for Aids therapy. Science249:1533–1544.
51.
MiyasakaTTanakaHBabaMHayakawaHWalkerRTBalzariniJSt De ClercqE (1989) A novel lead for specific anti HIV-1 agents 1–[(2 hydrowethoxy) methyl]-6–(phenylthio)thymine. Journal of Medicinal Chemistry32:2507–2509.
52.
MoogCWickALe BerPKirnA & AubertinAM (1994) Bicyclic imidazo derivatives, a new class of highly selective inhibitors for the human immunodeficiency virus type 1. Antiviral Research24:275–288.
53.
MosmannT (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. Journal of Immunological Methods65:55–63.
54.
MüllerBRestleTReinsteinJ & GoodyRS (1991) Interaction of fluorescently labelled didcoxynucleotides with HIV-1 reverse transcriptase. Biochemistry30:3709–3715.
55.
NanniRGDingJJaccobo-MolinaAHughesSH & ArnoldE (1993) Review of HIV-1 reverse transcriptase three-dimensional structure: implication for drug design. Perspectives in Drug Discovery and Design1:129–150.
56.
NunbergJHSchleifWABoorsEJO'BrienJAQuinteroJCHoffmanJMEminiEA & GoldmanME (1991) Viral resistance to human immunodeficiency virus type 1–specific pyridinone reverse transcriptase inhibitors. Journal of Virology65:4887–4892.
57.
PauwelsRBalzariniJScholsDBabaMDesmyterJRosenbergIHolyA & De ClercqE (1988) Phosphonylmethoxyerhyl purine derivative, a new class of anti-human immunodeficiency virus agents. Antimicrobial Agents and Chemotherapy32:1025–1030.
58.
PauwelsRAndriesKDesmyterJScholsDKuklaMJBreslinHJRaeymaeckersAVan GelderJWoestenborghsRHeykantsJSchellekensK & JanssenPA (1990) Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives. Nature343:470–474.
59.
PauwelsRAndriesKDebysserZVan DaelePScholsDStoffelsKDe VreeseRWoestenborghAMVandammeCCJanssenJAnneGCauwenberghJDesmyterJHeykantMJanssenGMJanssenACDe ClercqE & JanssenPA (1993) Potent and highly selective human immunodeficiency virus type 1 (HIV-1) inhibition by a scries of α-anilinophenylacetamide derivatives targeted at HIV-1 reverse transcriptase. Proceedings of the National Academy of Sciences, USA90:1711–1715.
60.
PauwelsRAndriesEDebyserZKuklaMJScholsDBreslinHJWoestenborghsRDesmyterJJanssenMACDe ClercqE & JanssenPAJ (1995) New tetrahydroimidazo[4,5,1-jk] [1,4]-benzo-diazepin-2 (l-H)-one-thione derivatives are potent inhibitors of human immunodeficiency virus type 1 replication and are synergistic with 2′,3′-dideoxynucleoside analogs. Antimicrobial Agents and Chemotherapy38:2863–2870.
RichmanDDFrichlMAGriecoMHGottliebMSVolberdingPALaskinOLLeedomJMGroopmanJEMildvanDHirschMSJacksonGODurackDT & Nusinoff-LehrmanS (1987) AZT collaborative working group. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS related complex. New England Journal of Medicine317:192–197.
63.
RichmanDShihCKLowryIRoseJProdanovichPGoffsS & GriffiriJ (1991) Human immunodeficiency virus type 1 mutants resistant to non-nucleoside inhibitors of reverse transcriptase arise in tissue culture. Proceedings of the National Academy of Sciences, USA88:11241–11245.
RobbinsMJHansske E LowNII & ParkJI (1984) Mild conversion of vicinal diols to alkenes. Efficient transformation of ribonucleosides into 2′-ene and 2′,3′-didcoxynuclcosides. Tetrahedron Letters25:367.
66.
RomeroDLBussoMTanCKReusserFPalmerJRPoppeSMAristoffPADowneyKMSoAGResnickL & TarpleyWG (1991) Non nucleoside reverse transcriptase inhibitors that potently and specifically block human immunodeficiency virus type 1 replication. Proceedings of the National Academy of Sciences, USA88:8806–8810.
67.
RomeroDLMorgeRAGerrinMJBilesCBassoMResnickLAlthausIWReusserFThomasRC & TarpleyWG (1993) Bis(heteroaryl)piperazine (BHAP) reverse transcriptase inhibitors; structure-activity relationships of novel substituted indole analogues and the identification of 1-[(5-methanesulfonamido-1H-indol-2-yl)-carbonyl]-4-[3-(1-methylethyl)amino]-pyridinyl piperazine monomethane sulfonate (U-90152S) a second-generation clinical candidate. Journal of Medicinal Chemistry36:1505–1508.
68.
RongFG & SolowayAH (1994) Synthesis of 5-tethered carboranecontaining pyrimidine nucleosides as potential agents for DNA incorporation. Nucleosides and Nucleotides13:2021–2034.
69.
RongFCSolowayAHIkedaS & IvesDH (1995) Synthesis and biochemical activity of 5-tethered carboranecontaining pyrimidine nucleosides as potential agents for DNA incorporation. Nucleosides & Nucleotides14:1873–1887.
70.
RuthJL & ChengYC (1981) Nucleoside analogues with clinical potential in anti-virus chemotherapy. The effect of several thymidine and 2′-deoxycytidine analogue 5′-triphosphates on purified human (α, β) and herpes simplex virus (type 1, 2) DNA polymerases. Molecular Pharmacology20:415–422.
71.
RuthJL & ChengYC (1982) Selective antiviral agents. The metabolism of 5-propyl-2′-deoxyuridine and effects on DNA synthesis in herpes simplex virus type 1 infections. Journal of Biological Chemistry257:10261–10266.
72.
SandströmEGByintonREKaplanJC & HirschMS (1985) Inhibition of T-cell lymphotropic virus type III in vitro by phosphonoformate. Lanceti:4075–4079.
73.
ScheitKH (1966) Die synthese der 5′-diphosphate von 5-methyl-uridin, 5-hydroxy methyl-uridin und 3,5-dimethyl-uridin. Chemische Berichte99:3884–3891.
74.
SchinaziRFChuCKPeckAMcMillanAMathiasRCannonDJongLSBeachJWChainBJeolaS & LiottaDC (1992) Activities of the form optical of 2′,3′-didcoxy-3′-thiarytidine BCH-189 against human immunodeficiency virus type 1 in human lymphocytes. Antimicrobial Agents & Chemotherapy36:672–676.
75.
SekineMSeioKSatohTSakamotoK & YokoyamaS (1993) Synthesis of uridylyl (3′-5′) uridine derivatives containing 5-(methylamino-methyl) uridine as a modified nucleoside found from E. Coli minor tRNA. Nucleosides & Nucleotides12:305–321.
76.
SommadossiJP & CarlisleR (1987) Toxicity of 3′-azido-3′-deoxythymidine and 9-(l,3 dihydroxy-2-propoxymethyl) guanine for normal human hematopoietic progenitor cells in vitro. Antimicrobial Agents & Chemotherapy31:452–454.
77.
SondersHYaoQBelleauBKrausJLNguyen-BaNSpiraB & WainbergMA (1991) Anti-human immunodeficiency virus type 1 activity and in vitro toxicity of 2′-deoxy-3′-thiacytidine BCH-189, a novel heterocyclic nucleoside analog. Antimicrobial Agents & Chemotherapy35:1386–1390.
78.
StaggMPCrettonEM & KiddL (1992) Clinical pharmacokinetics of 3′-azido-3′-deoxythymidine (zidovudine) and catabolites with formation of a toxic catabolite 3′-amino-3′-deoxythymidine, Clinical Pharmacology and Therapeutics51:668–676.
79.
St ClairMHMartinJLTudor-WilliamsGBachMCVavroCLKingDMKellamPKempSD & LarderBA (1991) Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science253:1557.
80.
TanakaHBabaMUbasawaMTakashimaHSekiyaKNittaIShigetaSWalkerRTDe ClercqE & MiyasakaT (1993) Synthesis and anti HIV activity of 2-, 3- and 4-substituted analogues of 1-[2 hydroxyethoxy)methyl]-6-(phenylthio)thymine. Journal of Medicinal Chemistry34:1394–1399.
81.
TanakaHTakashimaHUbasawaMSekiyaKNittaIBabaMShigetaSWalkerRTDe ClercqF. & MiyasakaT (1992) Synthesis and antiviral activity of deoxy analogs of 1-[(2-hydroxyethoxy)methyl]-6-phenylthio thymine HEPT as potent and selective anti-HIV-1 agents. Journal of Medicinal Chemistry35:4713–4719.
82.
VelazquezSAlvarezRSan-FelixAJimenoMLDe ClercqEBalzariniJ & CamarasaMJ (1995) Synthesis and anti-HIV activity of [AZT]-[TSAO] and [AZT]-[HEPT] dimers as potential multifunctional inhibitors of HIV-1 reverse transcriptase. Journal of Medicinal Chemistry38:1641–1649.
83.
VolberdingPALagakosSWKochMAPertinelliCMyersMWBoothDKBalfourHHRechmanRCBartlerrJAHirchMSMurphyRLHardyWDSoeiroRFischlMABartlettJGMeriganTCHyslopNERichmanDDValentineFT & CoreyL (1990) The Aids clinical trials group of the national institute of allergy and infection diseases. Zidovudine in a symptomatic human immunodeficiency virus infection. Nevj England Journal of Medicine322:941–949.
84.
YarchoanRThomasRVMainJPMcAterNDubinskyRMitsuyaHLawleyTJSafaiBMyersCEPernoCFKleckerRWWillsRWFischlMAMcNeilyMCPludaJMLeutherMCollinsJM & BroderS (1988) Phase I studies of 2′,3′-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine AZT. Lanceti:76–81.
85.
YarchoanRMitsuyaHThomasHPludaRVHartmanJMPernoNRMarczykCFAllainKSJohnsJP & BroderDC (1989) In vivo activity against HIV and favorable toxicity profile of 2′,3′-didcoxyinosine. Science245:412–415.
86.
YoungSD (1993) Non-nucleoside inhibitors of HIV-1 reverse transcriptase. Perpectives in Drug Discovery and Design1:181–192.
